Acucela Kicks off U.S. Study of Japanese Dry Eye Drug
Acucela Inc., of Seattle, began a Phase III trial of 2 percent rebamipide ophthalmic suspension for dry eye syndrome. The trial will support eventual U.S. regulatory submission for the product, already launched in Japan as Mucosta by Otsuka Pharmaceutical Co. Ltd.
Sign up for Perspectives FREE e-mail newsletter.
Outside the U.S.: 1-404-262-5423
Hours: Monday - Thursday, 8:30 am - 6:00 pm EST
Friday, 8:30am - 4:30 pm EST